WAVE LIFE SCIENCES LTD. Operating Cash Flow
WAVE LIFE SCIENCES LTD. (WVE) reported Operating Cash Flow of -$113.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$53.58M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$59.55M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$33.78M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$44.67M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2025 was -$187.49M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2024 was -$151.03M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2023 was -$19.43M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2022 was -$127.78M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$53.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$113.14M 10-Q · filed 2026-07-30 | -$146.91M derived: sum of 3 quarters · filed 2026-07-30 | -$191.58M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$59.55M 10-Q · filed 2026-04-28 | -$93.33M derived: sum of 2 quarters · filed 2026-04-28 | -$138.00M derived: sum of 3 quarters · filed 2026-04-28 | -$184.01M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$33.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$78.44M derived: sum of 2 quarters · filed 2026-02-26 | -$124.45M derived: sum of 3 quarters · filed 2026-07-30 | -$187.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$44.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$90.68M derived: sum of 2 quarters · filed 2026-07-30 | -$153.72M 10-Q · filed 2025-11-10 | -$197.37M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$46.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$109.05M 10-Q · filed 2026-07-30 | -$152.70M derived: sum of 3 quarters · filed 2026-07-30 | -$199.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$63.04M 10-Q · filed 2026-04-28 | -$106.69M derived: sum of 2 quarters · filed 2026-04-28 | -$153.16M derived: sum of 3 quarters · filed 2026-04-28 | -$180.63M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$43.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$90.13M derived: sum of 2 quarters · filed 2026-02-26 | -$117.59M derived: sum of 3 quarters · filed 2026-02-26 | -$151.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$46.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$73.95M derived: sum of 2 quarters · filed 2025-11-10 | -$107.38M 10-Q · filed 2025-11-10 | -$140.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$27.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$60.90M 10-Q · filed 2025-07-30 | -$94.14M derived: sum of 3 quarters · filed 2026-02-26 | -$128.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$33.43M 10-Q · filed 2025-05-08 | -$66.67M derived: sum of 2 quarters · filed 2026-02-26 | -$101.13M derived: sum of 3 quarters · filed 2026-02-26 | -$138.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$33.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$67.70M derived: sum of 2 quarters · filed 2026-02-26 | -$104.95M derived: sum of 3 quarters · filed 2026-02-26 | -$19.43M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$34.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$71.71M derived: sum of 2 quarters · filed 2024-11-12 | $13.81M 10-Q · filed 2024-11-12 | -$19.63M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | -$37.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $48.27M 10-Q · filed 2024-08-08 | $14.82M derived: sum of 3 quarters · filed 2025-03-04 | -$10.82M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $85.52M 10-Q · filed 2024-05-10 | $52.08M derived: sum of 2 quarters · filed 2025-03-04 | $26.44M derived: sum of 3 quarters · filed 2025-03-04 | -$2.39M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | -$33.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$59.09M derived: sum of 2 quarters · filed 2025-03-04 | -$87.91M derived: sum of 3 quarters · filed 2025-03-04 | -$127.78M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$25.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$54.47M derived: sum of 2 quarters · filed 2023-11-09 | -$94.34M 10-Q · filed 2023-11-09 | -$101.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$28.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$68.69M 10-Q · filed 2023-08-03 | -$75.73M derived: sum of 3 quarters · filed 2023-08-03 | -$103.91M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$39.87M 10-Q · filed 2023-05-03 | -$46.91M derived: sum of 2 quarters · filed 2023-05-03 | -$75.09M derived: sum of 3 quarters · filed 2023-05-03 | -$84.49M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$35.22M derived: sum of 2 quarters · filed 2023-03-23 | -$44.62M derived: sum of 3 quarters · filed 2023-03-23 | -$88.99M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$28.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$37.59M derived: sum of 2 quarters · filed 2022-11-10 | -$81.96M 10-Q · filed 2022-11-10 | -$113.38M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$53.78M 10-Q · filed 2022-08-11 | -$85.19M derived: sum of 3 quarters · filed 2022-08-11 | -$105.36M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$44.38M 10-Q · filed 2022-05-12 | -$75.79M derived: sum of 2 quarters · filed 2022-05-12 | -$95.96M derived: sum of 3 quarters · filed 2022-05-12 | -$134.11M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$31.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$51.59M derived: sum of 2 quarters · filed 2022-03-03 | -$89.73M derived: sum of 3 quarters · filed 2022-03-03 | -$115.98M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$20.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$58.32M derived: sum of 2 quarters · filed 2021-11-10 | -$84.57M 10-Q · filed 2021-11-10 | -$145.81M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$38.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$64.39M 10-Q · filed 2021-08-05 | -$125.64M derived: sum of 3 quarters · filed 2021-08-05 | -$169.32M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$26.25M 10-Q · filed 2021-05-13 | -$87.49M derived: sum of 2 quarters · filed 2021-05-13 | -$131.17M derived: sum of 3 quarters · filed 2021-05-13 | -$164.10M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$61.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$104.92M derived: sum of 2 quarters · filed 2021-03-04 | -$137.85M derived: sum of 3 quarters · filed 2021-03-04 | -$188.23M 10-K · filed 2021-03-04 |
| 2019-09-30 | -$43.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$76.61M derived: sum of 2 quarters · filed 2020-11-09 | -$126.99M 10-Q · filed 2020-11-09 | -$159.81M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$32.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$83.31M 10-Q · filed 2020-08-10 | -$116.13M derived: sum of 3 quarters · filed 2020-08-10 | -$145.14M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$50.38M 10-Q · filed 2020-05-11 | -$83.20M derived: sum of 2 quarters · filed 2020-05-11 | -$112.21M derived: sum of 3 quarters · filed 2020-05-11 | -$40.82M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$32.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$61.83M derived: sum of 2 quarters · filed 2020-03-02 | $9.56M derived: sum of 3 quarters · filed 2020-03-02 | -$22.86M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$29.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $42.38M derived: sum of 2 quarters · filed 2019-11-05 | $9.96M 10-Q · filed 2019-11-05 | -$12.80M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $71.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $38.97M 10-Q · filed 2019-08-06 | $16.21M derived: sum of 3 quarters · filed 2020-03-02 | -$7.20M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$32.43M 10-Q · filed 2019-05-10 | -$55.18M derived: sum of 2 quarters · filed 2020-03-02 | -$78.59M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$22.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$46.16M derived: sum of 2 quarters · filed 2020-03-02 | -$83.67M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$23.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$60.92M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$37.51M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$31.93M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |